Phase I Master Protocol Evaluates BCMA-Directed CAR-T Therapies in R/R MM

Kite, a Gilead Company, is running a proof-of-concept master protocol to assess BCMA-specific CAR-T cell therapies—featuring an alternative binding domain—in patients with relapsed/refractory multiple myeloma, with long-term safety follow-up. This early-phase trial, conducted in Boston, Milwaukee, and Chicago, aims to advance the field of cell therapy in MM by validating novel approaches to long-term disease management.